Structure Therapeutics

Cancer Holds Pharma R&D Lead as Obesity Pipeline Swells 30.7% and Rare Disease Share Rises

- Oncology still accounts for 38.6% of newly identified drug candidates, but the number of cancer drugs in development fell 4.6% for a second consecutive year. - The anti-obesity category grew 30.7% to 588 drugs, and obesity entered the top 10 indications for the first time with 576 candidates. - Rare disease drugs slipped 1.3% to 7,618 candidates yet rose to 33.2% of the overall pipeline, with Novartis leading at 116 candidates. - Lilly's retatrutide delivered 28.3% average weight loss at 80 weeks, while Novo Nordisk's CagriSema missed noninferiority to tirzepatide.